title: [Immunotherapy for lung cancer by streptococcal preparation OK-432].
abstract: To evaluate the clinical efficacy of OK-432 immunotherapy, patients admitted between 1975 and 1982 were randomized into two groups: An immunochemotherapy (IM-C) group and a chemotherapy (control) group. For each group, a fixed chemotherapy was administered using a combination of three drugs. The survival rates of cases with non-small cell carcinoma were evaluated at the end of 1987. One hundred and fifty-seven cases in the IM-C group and 148 in the control group were eligible for evaluation of long-term survival rates. Statistically significant improvement of the survival rates in the IM-G group were noted in the following items: All cases, resected cases, non-resected cases, resected stage I + II cases, resected stage III cases, completely resected cases, incompletely resected cases, and cases with epidermoid carcinoma. However, in comparison of adenocarcinoma there was no significant difference between the two groups. SU-polysaccharide skin test and natural killer activity were the best immunological parameters during the OK-432 therapy. To intensify the effects of immunotherapy, a possibility of regional immunotherapy was studied following some experimental works. Regional infusion of LAK cells (induced by incubation of patient's lymphocytes with rIL-2) through bronchial artery after regional infusion of OK-432 and chemotherapeutics showed favorable effect for advanced lung cancer. Future prospect of these regional adoptive immunotherapy was discussed.
authors.affiliation: Department of Surgery, Kanazawa University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: J
authors.initials: J
authors.lastname: Shimizu
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Hashizume
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Iwa
mesh_terms: D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000096:biosynthesis; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D001688:Biological Products; D007376:Interleukin-2; D010844:Picibanil